HK1153229A1 - Minicell compositions and methods - Google Patents
Minicell compositions and methodsInfo
- Publication number
- HK1153229A1 HK1153229A1 HK11107237.5A HK11107237A HK1153229A1 HK 1153229 A1 HK1153229 A1 HK 1153229A1 HK 11107237 A HK11107237 A HK 11107237A HK 1153229 A1 HK1153229 A1 HK 1153229A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- minicell compositions
- minicell
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/5432—Liposomes or microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35984302P | 2002-02-25 | 2002-02-25 | |
US10/154,951 US20030194798A1 (en) | 2001-05-24 | 2002-05-24 | Minicell compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1153229A1 true HK1153229A1 (en) | 2012-03-23 |
Family
ID=27767433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107237.5A HK1153229A1 (en) | 2002-02-25 | 2011-07-12 | Minicell compositions and methods |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP2272946B9 (de) |
AU (1) | AU2002318168B2 (de) |
CA (1) | CA2517027A1 (de) |
ES (1) | ES2541351T3 (de) |
HK (1) | HK1153229A1 (de) |
WO (1) | WO2003072014A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
CA2463631C (en) * | 2001-10-15 | 2012-07-03 | Engeneic Gene Therapy Pty Limited | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
PL1694361T3 (pl) | 2003-12-09 | 2011-08-31 | Engeneic Molecular Delivery Pty Ltd | Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii |
CN102028953B (zh) * | 2004-02-02 | 2013-10-30 | 恩杰内克分子递送有限公司 | 经细菌来源的完整微细胞在体外和体内将药物靶向递送至哺乳动物细胞的组合物和方法 |
US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
JP4114075B2 (ja) * | 2004-02-16 | 2008-07-09 | ヒューマン・メタボローム・テクノロジーズ株式会社 | 遺伝子産物の機能同定方法及び結合物質同定方法 |
US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
WO2006055024A2 (en) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicells as vaccines |
ES2535235T3 (es) | 2004-08-26 | 2015-05-07 | Engeneic Molecular Delivery Pty Ltd | Administración de ácidos nucleicos funcionales a células de mamífero a través de minicélulas intactas obtenidas a partir de bacterias |
PL2712618T3 (pl) | 2006-06-23 | 2017-07-31 | Engeneic Molecular Delivery Pty Ltd. | Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne |
DK2675474T3 (en) | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
EP2758565A4 (de) * | 2011-09-23 | 2015-03-04 | Merck Sharp & Dohme | Zelloberflächenanzeige von liganden für insulin und/oder des insulin-wachstumsfaktor 1-rezeptors und anwendungen davon |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
RU2577138C1 (ru) * | 2014-11-25 | 2016-03-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ получения рекомбинантного белка sav-rgd |
EP3093043B1 (de) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implantat und abgabesystem für nervenstimulator |
CA3056801A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
US11812743B2 (en) | 2017-09-25 | 2023-11-14 | Agrospheres, Inc. | Compositions and methods for scalable production and delivery of biologicals |
AU2020205040A1 (en) * | 2019-01-04 | 2021-08-12 | Engeneic Molecular Delivery Pty Ltd | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
CN110669811A (zh) * | 2019-10-21 | 2020-01-10 | 天津大学 | 一种提高表面活性素产量的方法 |
EP4114423A4 (de) * | 2020-03-06 | 2024-05-01 | Endolytix Technology, Inc. | Zusammensetzungen und verfahren zur behandlung intrazellulärer bakterieller infektionen |
CN116087504B (zh) * | 2023-02-24 | 2023-08-15 | 上海碧云天生物技术有限公司 | 免疫磁珠保护液、其制备方法及应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4132769A (en) | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US5212071A (en) | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
US4311797A (en) | 1979-09-18 | 1982-01-19 | University Of Saskatchewan | Anucleated live E. coli vaccine |
US4497796A (en) | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
US4895724A (en) | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
US4839293A (en) | 1986-02-24 | 1989-06-13 | The Trustees Of Columbia University In The City Of New York | DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US4921790A (en) | 1987-04-24 | 1990-05-01 | Research Corporation | Tumor specific assay for CA125 ovarian cancer antigen |
US5654176A (en) | 1987-05-28 | 1997-08-05 | Amrad Corporation Limited | Fusion proteins containing glutathione-s-transferase |
US4963484A (en) | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5053489A (en) | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US4914021A (en) | 1988-03-04 | 1990-04-03 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
JPH04506148A (ja) | 1989-04-07 | 1992-10-29 | カンサーフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング) | ウロキナーゼ型プラスミノーゲン活性化因子レセプター |
US6261800B1 (en) | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
US5260432A (en) | 1989-06-22 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Human gamma retinoic acid receptor DNA |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5773024A (en) | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
ATE220421T1 (de) | 1990-02-26 | 2002-07-15 | Univ Leland Stanford Junior | Identifizierung und expression von insekten- steroidrezeptor-dns-sequenzen |
DE69131393T2 (de) | 1990-09-10 | 1999-11-04 | Takeda Chemical Industries, Ltd. | Menschlicher Rezeptor für luteinisierendes Hormon und Choriongonadotropin |
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
JP3050424B2 (ja) | 1991-07-12 | 2000-06-12 | 塩野義製薬株式会社 | ヒトエンドセリンリセプター |
US6025165A (en) | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
GB2265375A (en) | 1992-03-16 | 1993-09-29 | Merck & Co Inc | Human nuerokinin-3 receptor |
US6225080B1 (en) | 1992-03-23 | 2001-05-01 | George R. Uhl | Mu-subtype opioid receptor |
US5532347A (en) | 1992-04-10 | 1996-07-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | DNA encoding α melanocyte stimulating hormone receptor |
US5837521A (en) | 1993-04-08 | 1998-11-17 | State Of Oregon | Nucleic acids encoding the γ-MSH receptor MC3-R |
US6313279B1 (en) | 1992-05-01 | 2001-11-06 | Eli Lilly And Company | Human glutamate receptor and related DNA compounds |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
DK0656007T3 (da) | 1992-08-13 | 2003-10-06 | Univ California | Delta opioidreceptor-gener |
US6300087B1 (en) | 1992-11-03 | 2001-10-09 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonin receptor (5-HT4B) and uses thereof |
WO1994012626A1 (en) | 1992-11-20 | 1994-06-09 | University Of Medicine & Dentistry Of New Jersey | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins |
WO1994018562A1 (en) | 1993-02-05 | 1994-08-18 | Epigen, Inc. | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
US6258556B1 (en) | 1993-02-26 | 2001-07-10 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA and genomic clones encoding human μ opiate receptor and the purified gene product |
US6235496B1 (en) | 1993-03-08 | 2001-05-22 | Advanced Research & Technology Institute | Nucleic acid encoding mammalian mu opioid receptor |
WO1994024284A1 (en) | 1993-04-20 | 1994-10-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
US5716789A (en) | 1993-07-26 | 1998-02-10 | Cor Therapeutics, Inc. | Method to determine ligands, agonist and antagonist of C140 receptor |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
AU695641B2 (en) | 1993-09-20 | 1998-08-20 | Novartis Ag | Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds |
PT728200E (pt) | 1993-11-08 | 2006-12-29 | Sanofi Pasteur Ltd | Genes de receptores de transferrina de haemophilus |
US6248554B1 (en) | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
US6225531B1 (en) | 1994-06-17 | 2001-05-01 | Kirin Beer Kabushiki Kaisha | Glucan elicitor receptor, DNA molecule coding therefor, fungus-resistant plants transformed with the DNA molecule and method for creating the plants |
GB9416536D0 (en) | 1994-08-16 | 1994-10-12 | Karobio Ab | Orphan receptor |
US6274708B1 (en) | 1994-09-05 | 2001-08-14 | Amrad Operations Pty Ltd. | Mouse interleukin-11 receptor |
US6306622B1 (en) | 1994-11-04 | 2001-10-23 | The Procter & Gamble Co. | cDNA encoding a BMP type II receptor |
US6245893B1 (en) | 1994-12-17 | 2001-06-12 | Smithkline Beecham P.L.C. | Receptor that binds anti-convulsant compounds |
JP3064015B2 (ja) | 1995-01-26 | 2000-07-12 | メルク フロスト カナダ アンド カンパニー | プロスタグランジンレセプターdp |
US6111079A (en) | 1995-06-05 | 2000-08-29 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefore |
US6025191A (en) | 1995-06-07 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof |
US6291207B1 (en) | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6017721A (en) | 1995-10-18 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Chromatographic method and device for preparing blood serum for compatibility testing |
US6048539A (en) | 1995-11-02 | 2000-04-11 | Connaught Laboratories Limited | Lactoferrin receptor protein |
US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
US6268214B1 (en) | 1996-04-04 | 2001-07-31 | Roche Diagnostics Gmbh | Vectors encoding a modified low affinity nerve growth factor receptor |
US5965392A (en) | 1996-04-08 | 1999-10-12 | Bayer Corporation | Neuropeptide Y receptor Y5 and nucleic acid sequences |
US6271347B1 (en) | 1996-04-26 | 2001-08-07 | Merck & Co., Inc. | Eosinophil eotaxin receptor |
US6258944B1 (en) | 1996-05-06 | 2001-07-10 | Merck & Co., Inc. | OB receptor isoforms and nucleic acids encoding them |
AU4344197A (en) | 1996-09-13 | 1998-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Car, a novel coxsackievirus and adenovirus receptor |
EP0960125A4 (de) | 1996-12-27 | 2002-09-25 | Merck & Co Inc | GALANIN REZEPTOR GalR2 UND NUKLEOTIDE WELCHE DIESEN KODIEREN |
ATE321855T1 (de) | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US6242251B1 (en) | 1997-03-18 | 2001-06-05 | Eli Lilly And Company | Rhesus neuropeptide Y5 receptor |
AU6769998A (en) | 1997-03-26 | 1998-10-20 | Board Of Regents, The University Of Texas System | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes |
JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
US5951951A (en) | 1997-04-30 | 1999-09-14 | Medtronic, Inc. | Platelet function evaluation technique for citrated whole blood |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
ATE253111T1 (de) | 1997-08-20 | 2003-11-15 | Univ California | Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung |
US6222015B1 (en) | 1997-09-08 | 2001-04-24 | Merck & Co., Inc. | Estrogen receptor |
WO1999024569A1 (fr) | 1997-11-11 | 1999-05-20 | Ono Pharmaceutical Co., Ltd. | Recepteur d'acide lysophosphatidique humain et utilisation dudit recepteur |
US6210967B1 (en) | 1997-12-10 | 2001-04-03 | Synaptic Pharmaceutical Corporation | DNA encoding a mammalian LPA receptor and uses thereof |
EP1086223B1 (de) | 1998-06-01 | 2009-07-29 | Agensys, Inc. | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
US6248520B1 (en) | 1998-07-06 | 2001-06-19 | The Rockefeller University | Nucleic acid molecules encoding nuclear hormone receptor coactivators and uses thereof |
US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
WO2002072759A2 (en) * | 2001-03-07 | 2002-09-19 | Children's Medical Center Corporation | Method to screen peptide display libraries using minicell display |
US20030166099A1 (en) * | 2001-06-05 | 2003-09-04 | Sabbadini Roger A. | Minicells comprising membrane proteins |
CA2463631C (en) * | 2001-10-15 | 2012-07-03 | Engeneic Gene Therapy Pty Limited | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
-
2002
- 2002-05-28 WO PCT/US2002/016877 patent/WO2003072014A2/en not_active Application Discontinuation
- 2002-05-28 CA CA002517027A patent/CA2517027A1/en not_active Abandoned
- 2002-05-28 AU AU2002318168A patent/AU2002318168B2/en not_active Expired
- 2002-05-28 ES ES10008869.9T patent/ES2541351T3/es not_active Expired - Lifetime
- 2002-05-28 EP EP10008869.9A patent/EP2272946B9/de not_active Revoked
- 2002-05-28 EP EP20110000796 patent/EP2390308A1/de not_active Withdrawn
- 2002-05-28 EP EP02747872A patent/EP1487965A4/de not_active Withdrawn
-
2011
- 2011-07-12 HK HK11107237.5A patent/HK1153229A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1487965A2 (de) | 2004-12-22 |
AU2002318168B2 (en) | 2007-12-13 |
EP2272946A3 (de) | 2011-07-27 |
WO2003072014B1 (en) | 2004-04-22 |
EP2272946B9 (de) | 2015-06-24 |
AU2002318168A1 (en) | 2003-09-09 |
WO2003072014A3 (en) | 2004-02-12 |
WO2003072014A2 (en) | 2003-09-04 |
EP2272946A2 (de) | 2011-01-12 |
CA2517027A1 (en) | 2003-09-04 |
EP2390308A1 (de) | 2011-11-30 |
ES2541351T3 (es) | 2015-07-17 |
EP1487965A4 (de) | 2006-11-15 |
EP2272946B1 (de) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1153229A1 (en) | Minicell compositions and methods | |
GB0411940D0 (en) | Methods and compositions | |
EP1701725A4 (de) | Verfahren und zusammensetzungen | |
AU2002357119A8 (en) | Mitocidal compositions and methods | |
EP1545481A4 (de) | Zusammensetzungen und verfahren für die kombinierte chemotherapie | |
GB0222091D0 (en) | Dental compositions and methods | |
AU2003256805A8 (en) | Compounds compositions and methods | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
GB0208081D0 (en) | Skincare compositions and methods | |
AU2003275268A8 (en) | Hemostatic compositions and methods | |
AU2003297595A8 (en) | Atm kinase compositions and methods | |
GB0202059D0 (en) | Chemical compositions and methods | |
AU2002357748A8 (en) | Osteopontin-related compositions and methods | |
AU2003213120A8 (en) | Human rnase iii and compositions and uses thereof | |
GB2384705B (en) | Cosmetic and related compositions | |
EP1583557A4 (de) | Vakzine-zusammensetzungen und verfahren | |
AU2002366809A8 (en) | Syn3 compositions and methods | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
GB0207224D0 (en) | Tenascin-W compositions and uses thereof | |
GB0325942D0 (en) | Compositions and uses thereof | |
AU2002359869A8 (en) | Pak5-related compositions and methods | |
AU2003245524A8 (en) | Cryosurgery compositions and methods | |
GB0330062D0 (en) | Compositions and methods | |
GB0313059D0 (en) | Compositions and method | |
GB0214800D0 (en) | Novel use and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210528 |